Spectral Medical Provides Update on Tigris Clinical Trial - BioSpace
Spectral Medical Inc. updates on Tigris trial for PMX hemoperfusion in septic shock treatment, showing positive outcomes. 40 patients randomized, 14 sites active. PMX aims to reduce 28-day mortality, with potential FDA approval. Spectral also advances renal replacement therapy platforms.
Reference News
Spectral Medical Provides Update on Tigris Clinical Trial - BioSpace
Spectral Medical Inc. updates on Tigris trial for PMX hemoperfusion in septic shock treatment, showing positive outcomes. 40 patients randomized, 14 sites active. PMX aims to reduce 28-day mortality, with potential FDA approval. Spectral also advances renal replacement therapy platforms.